VJHemOnc is committed to improving our service to you

COMy 2019 | Rationale for NK-cell therapy in myeloma

VJHemOnc is committed to improving our service to you

Michael O’Dwyer

Here, Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the importance of fully functional NK-cells, which mediate antibody-dependant cytotoxicity, in multiple myeloma. At the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France, Prof. O’Dwyer also speaks of the challenges of CAR T-cell administration as a therapy, and how anti-CD38 CAR NK-cells could selectively target myeloma cells.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter